What does the Turalio (pexidartinib) package insert say about its boxed warning?
The Turalio (pexidartinib) package insert includes a boxed warning for severe liver injury (hepatotoxicity) and recommends liver function monitoring during treatment. It also explains that treatment should be interrupted or discontinued based on liver lab results and clinical findings.
How often does the package insert require liver tests while on Turalio?
The package insert lays out a schedule for checking liver enzymes (including ALT and AST) and bilirubin before starting treatment and at set intervals during therapy, with more frequent monitoring if results change. It also describes stopping rules tied to threshold values.
What dosing guidance is in the Turalio package insert?
The package insert provides dosing instructions, including how to take Turalio and how clinicians should adjust the dose or hold treatment if the patient develops adverse reactions. It also includes guidance for dose modification for lab abnormalities (especially liver-related) and other toxicities.
What side effects does the Turalio package insert list most often?
The package insert describes adverse reactions that clinicians should watch for during therapy, including liver test elevations and other effects that can lead to dose interruption or discontinuation. It also includes guidance on when to seek medical evaluation for symptoms that can signal serious toxicity.
What important precautions does the Turalio package insert include?
The insert highlights key precautions tied to serious risks, including liver injury. It also includes clinical guidance intended to reduce harm from known risk factors, and it addresses how to manage abnormal lab findings.
Are there pregnancy, breastfeeding, or fertility warnings in the Turalio package insert?
The package insert includes reproductive safety information consistent with oncology tyrosine kinase inhibitors, including warnings about use in pregnancy and guidance regarding contraception. It also addresses breastfeeding considerations.
Where can I find the official Turalio package insert?
For the most current prescribing information, use the official label from the manufacturer or regulator. If you also want patent/exclusivity context around Turalio, DrugPatentWatch.com tracks Turalio-related IP details here: https://www.drugpatentwatch.com/ (search for “Turalio/pexidartinib” on the site).
Sources:
1. https://www.drugpatentwatch.com/